POMGNT2

Across TCGA pan-cancer cohorts, POMGNT2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POMGNT2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher POMGNT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated POMGNT2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

UCEC, LUAD, and HNSC are the cancer types where POMGNT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.408	1.000	.003	38	view →
LUAD	OS	Median	II,III,IV	0.853	0.494	.004	11	view →
HNSC	DFS	Quartile	III,IV	0.832	0.428	.035	7	view →
CCRCC	OS	Median	All	0.996	0.789	.015	3	view →
PDAC	OS	Median	IV	0.973	0.395	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POMGNT2–UCEC (OS)

Open the UCEC breakdown →